Apogee Therapeutics (NASDAQ:APGE) Given New $130.00 Price Target at Canaccord Genuity Group

Apogee Therapeutics (NASDAQ:APGE) had its price objective upped by Canaccord Genuity Group from $89.00 to $130.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently commented on APGE. Craig Hallum reiterated a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, January 7th. Wedbush raised their target price on Apogee Therapeutics from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They set a “buy” rating and a $103.00 target price for the company. Stephens initiated coverage on Apogee Therapeutics in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target for the company. Finally, Royal Bank Of Canada cut their price target on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Apogee Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $110.43.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $73.00 on Tuesday. The firm’s 50 day moving average price is $71.16 and its two-hundred day moving average price is $63.95. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $84.56. The stock has a market cap of $5.07 billion, a PE ratio of -17.30 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, sell-side analysts predict that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 18,700 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00. Following the completion of the transaction, the insider directly owned 212,523 shares of the company’s stock, valued at approximately $16,542,790.32. The trade was a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. This trade represents a 1.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,839,700 shares of company stock worth $140,118,083. Corporate insiders own 42.77% of the company’s stock.

Institutional Trading of Apogee Therapeutics

A number of large investors have recently bought and sold shares of APGE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after buying an additional 694 shares during the period. Millennium Management LLC boosted its holdings in shares of Apogee Therapeutics by 100.0% in the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after buying an additional 130,164 shares during the period. Creative Planning bought a new stake in shares of Apogee Therapeutics during the second quarter worth $392,000. Handelsbanken Fonder AB increased its position in shares of Apogee Therapeutics by 13.3% during the second quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock worth $369,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Apogee Therapeutics by 7.4% during the second quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after acquiring an additional 1,907 shares during the period. 79.04% of the stock is owned by institutional investors.

Key Stories Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 Part A data for zumilokibart (APG777) showed durable maintenance and deepening of responses with every‑3‑month and every‑6‑month dosing (e.g., 75% and 85% maintained EASI‑75), supporting the drug’s infrequent‑dosing value proposition. GlobeNewswire: 52‑Week Data
• Positive Sentiment: Analysts reacted quickly with multiple buy ratings and big price‑target increases (Guggenheim, Canaccord, Citi, BTIG), lifting sentiment that the program could support late‑stage development or M&A interest. Benzinga: Analyst Upgrades
• Positive Sentiment: Investor write‑ups and media coverage highlighted the favorable maintenance results and potential next catalysts (Part B induction data in Q2 and possible phase‑3 start in H2 2026), sustaining bullish narrative. Seeking Alpha: Strong Buy / Catalyst Summary
• Neutral Sentiment: Company held a conference call/webcast to review the Part A 52‑week data, providing more transparency on durability and safety that investors can digest for modeling. GlobeNewswire: Conference Call
• Neutral Sentiment: Short‑interest notices in the feed show zero reported short shares (likely a data artifact); they do not provide meaningful evidence of positioning pressure.
• Negative Sentiment: Apogee announced a proposed $300 million underwritten public offering (with up to $45M option), which raises dilution risk and often triggers selling pressure after a rally — the most likely proximate cause of the intraday pullback. GlobeNewswire: Offering Announcement

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.